Meningococcal ACWY-CRM conjugate vaccine

BIOLOGICAL2 trials

Sponsors

Novartis Vaccines

Conditions

Meningococcal Disease

Phase 3

Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age

CompletedNCT00329849

Novartis VaccinesMeningococcal Disease

Start: 2006-05-31End: 2007-03-31Updated: 2018-10-09

Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.

CompletedNCT01973218

Novartis VaccinesMeningococcal Disease

Start: 2013-11-30End: 2014-04-30Updated: 2015-10-30

Related Papers

Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea--A randomised trial.

2016-01-2812 citations